SEEL vs. ARDS, PRFX, VIRX, PXMD, UPC, TFFP, SRNE, NEXI, HSTO, and SMFL
Should you be buying Seelos Therapeutics stock or one of its competitors? The main competitors of Seelos Therapeutics include Aridis Pharmaceuticals (ARDS), PainReform (PRFX), Viracta Therapeutics (VIRX), PaxMedica (PXMD), Universe Pharmaceuticals (UPC), TFF Pharmaceuticals (TFFP), Sorrento Therapeutics (SRNE), NexImmune (NEXI), Histogen (HSTO), and Smart for Life (SMFL). These companies are all part of the "pharmaceutical products" industry.
Seelos Therapeutics vs.
Seelos Therapeutics (NASDAQ:SEEL) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation, community ranking and media sentiment.
23.4% of Seelos Therapeutics shares are held by institutional investors. Comparatively, 9.7% of Aridis Pharmaceuticals shares are held by institutional investors. 1.1% of Seelos Therapeutics shares are held by company insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Aridis Pharmaceuticals has higher revenue and earnings than Seelos Therapeutics.
In the previous week, Seelos Therapeutics' average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.
Aridis Pharmaceuticals received 51 more outperform votes than Seelos Therapeutics when rated by MarketBeat users. However, 66.36% of users gave Seelos Therapeutics an outperform vote while only 61.00% of users gave Aridis Pharmaceuticals an outperform vote.
Seelos Therapeutics has a beta of 1.94, meaning that its stock price is 94% more volatile than the S&P 500. Comparatively, Aridis Pharmaceuticals has a beta of 9.82, meaning that its stock price is 882% more volatile than the S&P 500.
Seelos Therapeutics has a net margin of 203.13% compared to Aridis Pharmaceuticals' net margin of 0.00%.
Summary
Aridis Pharmaceuticals beats Seelos Therapeutics on 6 of the 9 factors compared between the two stocks.
Get Seelos Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SEEL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Seelos Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SEEL) was last updated on 2/22/2025 by MarketBeat.com Staff
